Can I read Advances in Immunotherapeutics in Pancreatic Ductal Adenocarcinoma on EtoBox?

Advances in Immunotherapeutics in Pancreatic Ductal Adenocarcinoma by Chouari, Tarak (author);La Costa, Francesca Soraya (author);Merali, Nabeel (author);Jessel, Maria-Danae (author);Sivakumar, Shivan (author);Annels, Nicola (author);Frampton, Adam E. (author) is a Medicine article available to read on EtoBox.

What is Advances in Immunotherapeutics in Pancreatic Ductal Adenocarcinoma about?

## Simple Summary Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer, responsible for the majority of cases and ranking seventh as a leading cause of cancer-related deaths. It is difficult to treat because is it often detected at advanced stages, there are no effective screening tests available, and patients can develop resistance to standard treatments like chemotherapy and radiation. Recent interest has involved immunotherapy, which stimulate the immune system to recognise and attack cancer cells. Therefore, our paper aims to summarise the findings of studies investigating immunotherapies in PDAC and we discuss the limitations of such therapies and avenues of future research. In a bid to address the outcomes associated with the disease. ## Abstract Pancreatic ductal adenocarcinoma (PDAC) accounts for up to 95% of all pancreatic cancer cases and is the seventh-leading cause of cancer death. Poor prognosis is a result of late presentation, a lack of screening tests and the fact some patients develop resistance to chemotherapy and radiotherapy. Novel therapies like immunotherapeutics have been of recent interest in pancreatic cancer. However, this f

Who reads Advances in Immunotherapeutics in Pancreatic Ductal Adenocarcinoma?

Author

Chouari, Tarak (author);La Costa, Francesca Soraya (author);Merali, Nabeel (author);Jessel, Maria-Danae (author);Sivakumar, Shivan (author);Annels, Nicola (author);Frampton, Adam E. (author)

Publisher

MDPI AG

Published

2023

Field

Medicine (Health Sciences)